Pancreatic cancer is particularly refractory to modern therapies, with a 5-year survival rate for patients at a dismal 8%. One of the significant barriers to effective treatment is the immunosuppressive pancreatic tumor microenvironment and development of resistance to treatment. New treatment options to increase both the survival and quality of life of patients are urgently needed. This study reports on a new non-cannabinoid, non-psychoactive derivative of cannabis, termed FBL-03G, with the potential to treat pancreatic cancer. In vitro results show major increase in apoptosis and consequential decrease in survival for two pancreatic cancer models- Panc-02 and KPC pancreatic cancer cells treated with varying concentrations of FBL-03G and radiotherapy. Meanwhile, in vivo results demonstrate therapeutic efficacy in delaying both local and metastatic tumor progression in animal models with pancreatic cancer when using FBL-03G sustainably delivered from smart radiotherapy biomaterials. Repeated experiments also showed significant (P < 0.0001) increase in survival for animals with pancreatic cancer compared to control cohorts. The findings demonstrate the potential for this new cannabis derivative in the treatment of both localized and advanced pancreatic cancer, providing impetus for further studies toward clinical translation.
Pancreatic ductal adenocarcinoma is an antagonistic internecine ailment of the exocrine pancreas with < 8% of patients surviving within a 5-year period (1, 2). A major challenge shared by pancreatic cancers is its aggressiveness, which often metastasizes to other organs before the patient is even diagnosed (3, 4). [Read More @ Frontiers in Oncology]
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
Notify me of follow-up comments by email.
Notify me of new posts by email.
The New York State Department of Labor has released new guidance regarding legalized recreational marijuana use and the workplace. According to that new guidance, employers must cite “articulable symptoms of impairment” in almost any effort to take action against an employee due to marijuana use. That means an employer must provide “objectively observable” evidence that…
Vermont’s Cannabis Control Board estimates that spending on recreational marijuana in Vermont could reach $225 million annually by 2025, which would translate to nearly $46 million in new state taxes. The figures are just some of the news from a highly anticipated report the board released last Friday. The 64-page document lays the groundwork for…
The initiative, promoted by independent legislator Zoila Rosa Volio, received the affirmative vote of 33 legislators, while 13 voted against it, after extensive discussion and the opposition of several legislators, mainly from the Restauración Nacional, Nueva República, Integración Nacional (PIN), and independent Shirley Díaz. The plan focuses on authorizing the production of cannabis plants, both…
A package of spending bills unveiled by a U.S. Senate committee on Monday evening does not include language that had prohibited D.C. from legalizing the sale of marijuana for the last six years, lifting a significant roadblock to the city’s plans to legalize and license dispensaries to sell the drug for recreational use. Earlier this summer the House of…